I know two people that have had neuroendocrine prostate cancer. They have passed. One of the major treatments that is done was chemotherapy with cabazitaxel with carboplatin included.

One person went to Austria and had actinium and Pluvicto treatments. Then came back and tried a PARP Inhibitor, but nothing worked.

For individuals with neuroendocrine prostate cancer (NEPC) that has metastasized to the liver, the median overall survival is typically around 10-14 months, according to a study published in the Journal of Clinical Oncology. This makes liver metastasis a particularly ominous site in metastatic castration-resistant prostate cancer (mCRPC).

If the neuroendocrine is not in the liver, then overall survival is usually less than 24 months.

There are studies being done for neuroendocrine cancer. You should definitely try to get into one of them. Here’s a list of the studies I know of

Neuroendocrine trials
From: MSKCC TargetDonc onclive ascopubs

There are several ongoing clinical studies targeting DLL3 in neuroendocrine prostate cancer (NEPC):
•

Memorial Sloan Kettering Cancer Center (MSK) is opening a clinical trial testing a radioactive ligand that targets DLL3 in people with metastatic NEPC. Patients will first be screened for DLL3 expression and, if eligible, will receive the targeted therapy.
•

The SKYBRIDGE trial (NCT05652686) is a phase 1/2 study evaluating peluntamig (PT217), which targets DLL3 and CD47, in patients with DLL3-expressing neuroendocrine carcinomas, including NEPC.
•

A phase 1b study of tarlatamab, a DLL3-targeted bispecific T-cell engager, is ongoing in patients with metastatic NEPC, showing manageable safety and encouraging anti-tumor activity in DLL3-positive cases (NCT04702737).
•

Other agents like HPN328, another DLL3-targeted T-cell engager, are also being tested in neuroendocrine prostate cancer.

These studies reflect a strong research focus on DLL3 as a therapeutic target for NEPC.
*